Lipid Droplet Accumulation Independently Predicts Poor Clinical Prognosis in High-Grade Serous Ovarian Carcinoma.
adipophilin
high-grade serous ovarian carcinoma
lipid droplet
ovarian cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Oct 2021
19 Oct 2021
Historique:
received:
01
10
2021
accepted:
16
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
High-grade serous ovarian carcinoma (HGSOC) is an epithelial cancer that accounts for most ovarian cancer deaths. Metabolic abnormalities such as extensive aerobic glycolysis and aberrant lipid metabolism are well-known characteristics of cancer cells. Indeed, accumulation of lipid droplets (LDs) in certain types of malignant tumors has been known for more than 50 years. Here, we investigated the correlation between LD accumulation and clinical prognosis. In 96 HGSOC patients, we found that high expression of the LD marker adipophilin was associated with poor progression-free and overall survival (
Identifiants
pubmed: 34680399
pii: cancers13205251
doi: 10.3390/cancers13205251
pmc: PMC8533764
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 20K09605
Organisme : Japan Society for the Promotion of Science
ID : 19K09784
Organisme : Japan Society for the Promotion of Science
ID : JP18K16776
Organisme : Japan Society for the Promotion of Science
ID : 20K18228
Organisme : Japan Society for the Promotion of Science
ID : 18K16809
Organisme : Japan Society for the Promotion of Science
ID : 18K16777
Organisme : an internal grant from Wakayama Medical University
ID : Tokutei-kenkyu-zyosei 2019
Organisme : an internal grant from Wakayama Medical University
ID : Tokutei-kenkyu-zyosei 2020
Références
Prostate Cancer Prostatic Dis. 2006;9(3):230-4
pubmed: 16683009
J Cutan Pathol. 2017 Mar;44(3):228-236
pubmed: 27886404
Hum Mutat. 2014 Jun;35(6):672-88
pubmed: 24665023
J Exp Clin Cancer Res. 2020 May 7;39(1):79
pubmed: 32381034
Blood Cancer J. 2013 May 31;3:e118
pubmed: 23727661
Adv Drug Deliv Rev. 2020;159:245-293
pubmed: 32711004
Histopathology. 2013 Mar;62(4):617-31
pubmed: 23347084
J Antibiot (Tokyo). 1995 Sep;48(9):937-41
pubmed: 7592058
Cancer Discov. 2015 Jun;5(6):652-67
pubmed: 25829424
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Nature. 2012 Nov 15;491(7424):364-73
pubmed: 23151579
Cell Death Dis. 2020 Feb 6;11(2):105
pubmed: 32029741
Trends Endocrinol Metab. 2016 Dec;27(12):893-903
pubmed: 27659144
Nature. 2011 Jun 29;474(7353):609-15
pubmed: 21720365
Gynecol Oncol. 2015 Aug;138(2):372-7
pubmed: 26050922
Cancer Cell. 2012 Mar 20;21(3):297-308
pubmed: 22439925
Cancer Res. 2007 Jul 1;67(13):6238-46
pubmed: 17616681
Cancer. 1963 Apr;16:521-5
pubmed: 14010714
J Cell Sci. 2002 Mar 15;115(Pt 6):1331-40
pubmed: 11884532
J Cell Biochem. 2002;84(4):675-86
pubmed: 11835393
Cancer Res. 1953 Jan;13(1):27-9
pubmed: 13032945
Nutrition. 2000 Mar;16(3):202-8
pubmed: 10705076
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Lab Invest. 2020 May;100(5):727-737
pubmed: 31857696
Am J Dermatopathol. 2015 Nov;37(11):809-21
pubmed: 26485238
J Lipid Res. 1987 Oct;28(10):1177-84
pubmed: 3681141
Biochemistry. 2019 Feb 12;58(6):499-503
pubmed: 30628446
Mol Endocrinol. 2004 Oct;18(10):2570-82
pubmed: 15243131
Sci Rep. 2014 Oct 29;4:6807
pubmed: 25351207
Ophthalmology. 2014 Apr;121(4):964-71
pubmed: 24290802
J Obstet Gynaecol Res. 2015 Feb;41(2):294-300
pubmed: 25160885
Oncogene. 2005 Nov 14;24(50):7455-64
pubmed: 16288292
J Antibiot (Tokyo). 1995 Sep;48(9):942-7
pubmed: 7592059
Nat Commun. 2013;4:2126
pubmed: 23839242
Mod Pathol. 2010 Apr;23(4):567-73
pubmed: 20118912
Histopathology. 2017 Jan;70(2):232-241
pubmed: 27467545
Nat Rev Cancer. 2007 Oct;7(10):763-77
pubmed: 17882277
J Biol Chem. 1984 Jan 25;259(2):815-9
pubmed: 6693397
Chin J Cancer. 2015 Jan;34(1):4-16
pubmed: 25556614
Atherosclerosis. 1995 Nov;118(1):145-53
pubmed: 8579624
Cancer Res. 1964 Aug;24:1108-15
pubmed: 14209404
Curr Cancer Drug Targets. 2004 May;4(3):235-56
pubmed: 15134532
Adv Anat Pathol. 2009 Sep;16(5):267-82
pubmed: 19700937
Atherosclerosis. 2007 Apr;191(2):290-7
pubmed: 16820149
Front Oncol. 2020 Oct 19;10:593017
pubmed: 33194756
J Clin Invest. 1932 Jul;11(4):677-82
pubmed: 16694069
Mol Med Rep. 2015 Oct;12(4):6037-42
pubmed: 26252415
Science. 1956 Aug 10;124(3215):269-70
pubmed: 13351639
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
Am J Pathol. 1998 Mar;152(3):759-69
pubmed: 9502418
Blood. 2000 Feb 1;95(3):1078-85
pubmed: 10648425
Cancer Res. 2002 Apr 15;62(8):2227-31
pubmed: 11956073
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cell Signal. 2003 May;15(5):463-9
pubmed: 12639709
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Atherosclerosis. 1995 Feb;113(1):71-8
pubmed: 7755657
J Clin Pathol. 1968 Sep;21(5):643-9
pubmed: 4880412
Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):379-85
pubmed: 16778565
Cardiovasc Drug Rev. 2003 Fall;21(3):199-215
pubmed: 12931254